Society: AGA

Background: Emerging evidence suggest that gut microbiota influence human health such as digestive functions and risk of sepsis. We hypothesize that using a novel oral microbiome formula (SIM01) can restore dysbiosis and reduce adverse clinical events among vulnerable individuals after COVID-19 vaccination.

Methods: In a single center, double-blind, randomized, parallel arm, placebo-controlled trial, we recruited COVID-19 vaccination-naïve subjects (elderlies aged ≥ 65 years and patients with type 2 diabetes). After receiving the first dose of COVID-19 vaccine (CoronaVac or BioNTech), eligible subjects were randomized in a 1:1 ratio to receive 3 months of SIM01 (containing 20 billion CFU of probiotics per day) or placebo (2 mg of vitamin C per day). Intervention (SIM01 or placebo) was initiated within 1 week of receiving COVID-19 vaccines to minimize confounding effects of COVID-19 infection. Follow-up assessments were arranged at 1 month and 3 months after second vaccine dose. Outcomes included (1) Adverse events (AEs), defined as new symptoms/diseases which exerted unfavourable impacts on subjects; and (2) Restoration of gut dysbiosis, defined as improvement in (i) gut microbiome composition and diversity; (ii) functional potential (i.e., MetaCyc pathway abundances); and (iii) proliferation of beneficial bacteria genus (i.e., bifidobacteria, eubacterium, roseburia and other short-chain fatty acids producers). Fecal microbiome analysis using shotgun metagenomic sequencing were performed at baseline and after 3 months. The study is registered in a clinical trial registry (NCT04884776).

Results: Between April 2021 and March 2022, of 497 subjects assessed for eligibility, we recruited 453 individuals (50.3% females; mean age 67.5 years). We randomly assigned 224 subjects to SIM01 and 229 to placebo. There was no difference in baseline characteristics between the two groups (Table 1). The incidence of AE (2.9% vs. 10.6%, p=0.002) and combined AE/serious AE (2.9% vs. 12.6%, p<0.001) were significantly lower in SIM01 group than placebo group at 1 month. Rates of AE (0% vs. 2.5%, p=0.053) and combined AE/serious AE (0% vs. 3.1%, p=0.025) remained significantly lower in SIM01 than placebo group at 3 months. Overall, 70.4%, 18.5%, and 11.1% of the AEs and serious AEs at 1 month included gastrointestinal disturbance, dermatological conditions and infections, respectively. Probiotics in SIM01 successfully colonized in the gut. SIM01, but not placebo, led to a significant increase in beneficial bacteria and butyrate producers in fecal samples, enterotype shift from bacteroides to bifidobacteria and a strengthened microbial ecology network at 3 months after second vaccine dose.

Conclusion: SIM01 restored gut dysbiosis, reduced adverse clinical outcomes and strengthened gut microbiome resilience in elderly people and diabetes patients after COVID-19 vaccination.

Background: Roseburia intestinalis is an anaerobic bacterium that has been shown to prevent intestinal inflammation by producing metabolites. We aimed to study the role of R. intestinalis in regulating colorectal tumorigenesis and immunotherapy through its metabolites.
Methods: The abundance of R. intestinalis was evaluated in stool samples of human CRC patients (n=444) and healthy subjects (n=575). The carcinogenic and immunomodulatory effects of R. intestinalis were studied in Apc^Min/+ and AOM-induced CRC mouse models. The metabolites produced by R. intestinalis were evaluated by untargeted metabolomic profiling and targeted gas chromatography-mass spectrometry (GC-MS). The bio-functions of R. intestinalis cultured medium and candidate metabolites were examined in CRC cell lines (HCT116, LoVo, SW480). The change of immune landscape was evaluated by multicolor flow cytometry and immunohistochemistry staining. The effects of R. intestinalis and its metabolites on anti-PD-1 efficacy were assessed in two syngeneic mouse models of CT26 (MSI-low) and MC38 (MSI-high).
Results: R. intestinalis was significantly depleted in stool samples of CRC patients compared to healthy controls (P<0.05). R. intestinalis administration significantly inhibited colorectal tumorigenesis by reducing tumor incidence, tumor number and tumor size in Apc^Min/+ mice, and further confirmed in AOM-induced CRC mice. R. intestinalis restored gut barrier functions as indicated by improved intestinal permeability and enhanced tight junction proteins ZO-1 and Claudin-3. R. intestinalis produced the metabolite butyrate which was identified as a functional component based on the metabolomic profiling assay and bio-functional validation in CRC cell lines. R. intestinalis significantly activated cytotoxic CD8⁺ T cells in colonic tumors of AOM-induced CRC mice. This was confirmed in both MC38 and CT26 orthotopic mouse models that R. intestinalis and butyrate suppressed tumor growth by inducing cytotoxic Granzyme B⁺, IFN-γ⁺ and TNF-α⁺ CD8⁺ T cells. Moreover, R. intestinalis and butyrate significantly improved anti-PD-1 efficacy in MSI-low CT26 orthotopic mouse model. Mechanistically, butyrate binds to TLR5 receptor of CD8⁺ T cells to induce its activity through activating NF-κB signaling. TLR5 inhibitor TH1020 abolished the effects of butyrate on activating CD8⁺ T cells and inducing NF-κB signalling.
Conclusions: R. intestinalis protects against CRC by producing butyrate in mice. R. intestinalis derived butyrate improved anti-PD-1 efficacy in CRC by inducing the functional CD8⁺ T cells through binding to the receptor of CD8⁺ T cells to activate the NF-κB signalling. R. intestinalis is a potential novel adjuvant therapy to augment anti-PD-1 efficacy against CRC.

Background: The recently enhanced capacity to test individuals for respiratory viruses, such as influenza virus (IAV), respiratory syncytial virus (RSV), and SARS/Cov-2, has led to the appreciation that severities of respiratory viral infections (RVI) are highly heterogenous ranging from asymptomatic infection to severe lung pathology and/or death.
Aim: We sought to investigate the hypothesis that intestinal microbiota composition is one factor that might influence severity of RVI.
Approach: Mice born with differing microbiomes were acquired from different vivaria or by administering mice the commensal bacteria segmented filamentous bacteria (SFB), which is naturally present in some vivaria. Nasal administration of H1N1 influenza virus (IAV) or respiratory syncytial virus (RSV) served as models of RVI.
Results: We observed that colonization of the intestine by SFB, naturally acquired or exogenously administered, lastingly protected mice against influenza virus (IAV) challenge, assessed by viral titers or clinical-type indices. Such protection was independent of type I and III interferons and adaptive immunity, IL-17/IL-22, and Stat1 signaling. Instead, it is associated with, and required, maintenance of alveolar macrophages (AMs), which, in mice lacking SFB, were quickly depleted as pandemic IAV replicated, leaving lung epithelial cells unguarded and thus highly prone to infection. Transplant of AMs from SFB+ to SFB- mice recapitulated the AM-emboldened phenotype and protected mice against IAV infection.
Conclusions: Gut microbiota composition can have dramatic impacts on alveolar macrophage phenotype and, consequently, be a major determinant RVI outcomes.

Background
Intestinal crypts form a pristine gut biogeographical niche, homing the intestinal stem cells and being the closest neighbors to underlying lamina propria. Initially believed to be sterile, the crypt lumen was recently shown to inhabit a conserved microbial population. However, the identity of the crypt-associated microbiota (CAM) remains elusive. The present study is among the first to illustrate the CAM composition in health and its deviation during ulcerative colitis (UC), and the effect of faecal microbiota transplantation along with an anti-inflammatory diet (FMT-AID) on the structure of this community.

Methods
Recto-sigmoidal biopsies from controls, and from patients with mild-moderate UC before and after FMT-AID (n=26), were subjected to methacarn-fixation, followed by paraffin-embedding, sectioning and laser-capture microdissection-assisted crypt isolation. DNA isolated from micro-dissected samples was subjected to 16S rRNA gene sequencing. The bacterial presence in colonic crypts was confirmed using fluorescence in-situ hybridization(FISH). Microbiome data analysis was carried out by using QIIME2 and R packages.

Results
FISH performed using pan-bacterial probes revealed the presence of sparse microbial clusters in colonic crypts, distinct from the overlying layer of Mucosa-associated microbiota (MAM), in both controls as well as in UC(Fig.1a and 1b). While MAM is dominated by members of phyla Firmicutes (45%) and Bacteroidetes (26%),CAM is comprised predominantly of aerobic members of Actinobacteria(54%) and Proteobacteria(38%), followed by minor proportions of Firmicutes(4%), Acidobacteria and Cyanobacteria (2% each). The significant members of CAM included aerobic genera -Cutibacterium(35%),Sphingobium(13%), Paracoccus(11%), Micrococcus(3%), Lawsonella(3%), Rothia(2%), Prauserella(2%), Kocuria, Corynebacterium, Acinetobacter and Brevundimonas (1% each)(Fig.1c and 1d). Analysis of CAM diversity in controls, and in patients with UC before and after FMT-AID, showed no significant alterations in the α- and β diversity matrices(Fig.1e and 1f).CAM demonstrated UC-associated dysbiosis of specific taxa which was restored after FMT-AID(Fig.2a and 2b). These FMT-restored CAM taxa correlated negatively with disease-associated parameters - Fecal calprotectin (FCP), Simple Clinical Colitis Activity Index (SCCAI) and Ulcerative Colitis Endoscopic Index of Severity (UCEIS)(Fig.2c and 2d). The positive effects of FMT-AID further refurbished the CAM-MAM interaction networks, which were obliterated in UC.(Fig.2e)

Conclusion
A gut bacterial community, enriched in aerobic bacteria, resides in the colonic crypts, and undergoes taxa-level alterations during UC and in response to FMT.

<b>Fig.1.</b> <b>(A and B)</b> Confocal images of Fluorescent in-situ hybridisation (FISH) of pan-bacterial probes performed on methacarn fixed tissue sections derived from the recto-sigmoid biopsies from non-UC controls and from patients with mild-moderate UC. Arrows indicate the crypt-associated microbiota (CAM), and ellipses indicate mucosa-associated microbiota (MAM) <b>(C and D)</b> Krona plots highlight the CAM and MAM compositions<b>(E)</b> Comparison of α diversity indices across the three groups – Controls, Pre-FMT (UC) and Post-FMT, assessed by Wilcoxon rank-sum test. <b>(F) </b>PCA plot depicting the clustering of the three sample groups of CAM on the basis of the Bray Curtis diversity indices. <b>(G)</b> Table depicting the ANOSIM values performed on the Aitchison Distances, for CAM and MAM samples. <b>(H) </b>Core bacterial features were identified along the three sample groups of CAM

Fig.1. (A and B) Confocal images of Fluorescent in-situ hybridisation (FISH) of pan-bacterial probes performed on methacarn fixed tissue sections derived from the recto-sigmoid biopsies from non-UC controls and from patients with mild-moderate UC. Arrows indicate the crypt-associated microbiota (CAM), and ellipses indicate mucosa-associated microbiota (MAM) (C and D) Krona plots highlight the CAM and MAM compositions(E) Comparison of α diversity indices across the three groups – Controls, Pre-FMT (UC) and Post-FMT, assessed by Wilcoxon rank-sum test. (F) PCA plot depicting the clustering of the three sample groups of CAM on the basis of the Bray Curtis diversity indices. (G) Table depicting the ANOSIM values performed on the Aitchison Distances, for CAM and MAM samples. (H) Core bacterial features were identified along the three sample groups of CAM

<b>Fig.2. (A and B)</b> Differentially abundant bacterial taxa between the Controls and UC and between UC Pre-FMT and Post-FMT were performed using R package DeSeq2<b>(C)</b> Biplot ordination depicting clustering of CAM abundance data and UC-associated clinical parameters (SCCAI, UCEIS and FCP levels)<b>(D) </b>Spearman correlation plots between the abundance of three CAM taxa found to be enhanced post-FMT (<i>Methylobacterium</i>, <i>Sphingobium</i> and <i>Rothia</i>) and the disease-associated clinical parameters – SCCAI, UCEIS and FCP levels.<b> (E) </b>Inter-niche interaction networks for five CAM members in post-FMT cohort constructed using Cytoscape-based CoNet application. The node colour depicts one of the four categories (as per the legend) in which each of the interactions falls. The node sizes vary as per the abundance of the taxa. Co-existence (or positive correlation) is represented by green edges, while mutual exclusion (or negative correlations) are denoted by red edges.

Fig.2. (A and B) Differentially abundant bacterial taxa between the Controls and UC and between UC Pre-FMT and Post-FMT were performed using R package DeSeq2(C) Biplot ordination depicting clustering of CAM abundance data and UC-associated clinical parameters (SCCAI, UCEIS and FCP levels)(D) Spearman correlation plots between the abundance of three CAM taxa found to be enhanced post-FMT (Methylobacterium, Sphingobium and Rothia) and the disease-associated clinical parameters – SCCAI, UCEIS and FCP levels. (E) Inter-niche interaction networks for five CAM members in post-FMT cohort constructed using Cytoscape-based CoNet application. The node colour depicts one of the four categories (as per the legend) in which each of the interactions falls. The node sizes vary as per the abundance of the taxa. Co-existence (or positive correlation) is represented by green edges, while mutual exclusion (or negative correlations) are denoted by red edges.

Background: Microbiota dysbiosis is known to contribute to the aetiology of irritable bowel syndrome (IBS). We conducted a randomized trial to assess the efficacy of two infusions of faecal microbiota transplantation (FMT) in patients with IBS and to determine gut microbial changes associated with clinical improvement.
Methods: This randomised, double-blind, placebo-controlled study randomised 56 patients with IBS fulfilling ROME III criteria at a ratio of 1:1 to FMT or placebo. Eligible patients received frozen FMT from healthy donors or placebo (saline) via the duodenal route at baseline and 1 month. Primary outcome was a reduction in the IBS symptoms at 3 months after FMT (response). Clinical response was defined as a decrease of 50 or more points in the total IBS symptom score. Secondary outcomes were overall symptom improvement, improvement in bloating and faecal microbiota composition assessed by shotgun metagenomic sequencing at 3 months after FMT. Open-label FMT (two infusions 1 month apart) was provided to patients who received placebo.
Results: Clinical response occurred in 52.2% of patients who received FMT and 37.5% who had placebo at 3 months (p=0.31). More patients who had FMT had general symptom relief (81.5% vs 53.6%, p=0.027) and bloating relief (75% vs 30%; p=0.0028) at 3 months compared with patients who had placebo. In the open-label extension, 57.9% and 82.0% of patients who received open-label FMT achieved clinical response and relief in bloating symptoms, respectively. Faecal microbiome of patients who received FMT showed a reduction in pathogenic bacteria such as Ruminococcus gnavus and enrichment of beneficial bacteria such as Lawsonibacter asaccharolyticus at 3 months compared with baseline, whilst no change in gut microbiome was observed in the placebo arm. Functional microbiota analyses showed that hydrogen sulphide-producing pathway, which was associated with the bloating in IBS patients, significantly decreased in patients who had FMT (p< 0.05) accompanied by a reduction in the total relative abundance of related bacteria, including Escherichia coli and several Klebsiella. There was no serious adverse event related to FMT.
Conclusions: Though FMT did not lead to overall IBS symptom improvement, more patients had general symptom and bloating improvement after FMT in association with reduction in hydrogen sulphide-producing bacteria in the gut. Further studies involving subtypes of IBS (bloating predominant) and well-defined donors are needed to personalized FMT treatment based on bacterial signatures for better clinical outcomes.

<b>Figure 1: Self-reported general symptom and bloating relief rate between groups at week 12 </b><br /> (A) Self-reported general symptom relief rate between groups at week 12. (B) Self-reported bloating relief rate between groups at week 12. FMT: faecal microbiota transplantation

Figure 1: Self-reported general symptom and bloating relief rate between groups at week 12
(A) Self-reported general symptom relief rate between groups at week 12. (B) Self-reported bloating relief rate between groups at week 12. FMT: faecal microbiota transplantation

Whitney Tang

Appearances